Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer

NCT03012100 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT03012100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03012100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 31, 2017
Completion date
July 31, 2026
Enrollment
280 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

bilateral breast carcinoma, breast inflammatory carcinoma, stage ib breast cancer ajcc v7, stage ii breast cancer ajcc v6 and v7, stage iia breast cancer ajcc v6 and v7, stage iib breast cancer ajcc v6 and v7, stage iii breast cancer ajcc v7, stage iiia breast cancer ajcc v7, stage iiib breast cancer ajcc v7, stage iiic breast cancer ajcc v7, triple-negative breast carcinoma, unilateral breast carcinoma